Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytek Biosciences, Inc.CTKB · Entity 5345 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytek Biosciences, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,679 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Exercise / conversion · Acquired 43,973 · Balance 59,679 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 33,333 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Grant · Acquired 33,333 · Balance 33,333 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2: 100% of the shares subject to the RSU Award shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-10 · Exercise / conversion · Disposed 43,973 · Balance 0 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4: 100% of the shares subject to the RSU Award vested on June 10, 2026. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.05 · Expires 2036-06-10 | Direct | 18,261 |
Reported balance
After 2026-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-10 · Grant · Acquired 18,261 · Balance 18,261 F3: 100% of the shares subject to the option shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027). |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2: 100% of the shares subject to the RSU Award shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027).
F3: 100% of the shares subject to the option shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027).
F4: 100% of the shares subject to the RSU Award vested on June 10, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 23:25 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 43,973 | $0.00 | $0.00 |
DisclosureSEC source: 0001902959-26-000001 · form4-06122026_110652.xml · derivative · entry 4 Imper Vera · CIK 0001902959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,973 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: 100% of the shares subject to the RSU Award vested on June 10, 2026. F4 · derivative.expiration_date: 100% of the shares subject to the RSU Award vested on June 10, 2026. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 23:25 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantDirector Stock Option (right to buy) · Derivative | 18,261 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001902959-26-000001 · form4-06122026_110652.xml · derivative · entry 3 Imper Vera · CIK 0001902959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,261 Underlying: Common Stock · 18,261 shares Expires 2036-06-10 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027). Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 23:25 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 33,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001902959-26-000001 · form4-06122026_110652.xml · derivative · entry 2 Imper Vera · CIK 0001902959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,333 Underlying: Common Stock · 33,333 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 100% of the shares subject to the RSU Award shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027). F2 · derivative.expiration_date: 100% of the shares subject to the RSU Award shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027). Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 23:25 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 43,973 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001902959-26-000001 · form4-06122026_110652.xml · nonDerivative · entry 1 Imper Vera · CIK 0001902959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 20:15 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantDirector Stock Option (right to buy) · Derivative | 23,809 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001415889-25-017838 · form4-06202025_080640.xml · derivative · entry 2 Imper Vera · CIK 0001902959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,809 Underlying: Common Stock · 23,809 shares Expires 2035-06-18 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of June 18, 2026 and the date of the Issuer's 2026 annual meeting of stockholders (provided such meeting is held in June 2026). Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 20:15 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 43,973 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017838 · form4-06202025_080640.xml · derivative · entry 1 Imper Vera · CIK 0001902959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,973 Underlying: Common Stock · 43,973 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 100% of the shares subject to the RSU Award shall vest on the earlier of June 18, 2026 and the date of the Issuer's 2026 annual meeting of stockholders (provided such meeting is held in June 2026). F2 · derivative.expiration_date: 100% of the shares subject to the RSU Award shall vest on the earlier of June 18, 2026 and the date of the Issuer's 2026 annual meeting of stockholders (provided such meeting is held in June 2026). Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 21:11 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 15,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-016319 · form4-06092025_090626.xml · derivative · entry 2 Imper Vera · CIK 0001902959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,706 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 100% of the shares subject to the RSU Award vested on June 5, 2025. F2 · derivative.expiration_date: 100% of the shares subject to the RSU Award vested on June 5, 2025. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 21:11 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 15,706 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-016319 · form4-06092025_090626.xml · nonDerivative · entry 1 Imper Vera · CIK 0001902959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 22:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantStock Option (right to buy) · Derivative | 23,076 | $0.00 Strike: $5.73 | $0.00 |
DisclosureSEC source: 0001415889-24-016077 · form4-06072024_100635.xml · derivative · entry 2 Imper Vera · CIK 0001902959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,076 Underlying: Common Stock · 23,076 shares Expires 2034-06-05 Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 22:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 15,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016077 · form4-06072024_100635.xml · derivative · entry 1 Imper Vera · CIK 0001902959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,706 Underlying: Common Stock · 15,706 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 100% of the shares subject to the RSU Award shall vest on June 5, 2025. F2 · derivative.expiration_date: 100% of the shares subject to the RSU Award shall vest on June 5, 2025. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 22:39 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantStock Option (right to buy) · Derivative | 30,242 | $0.00 Strike: $8.38 | $0.00 |
DisclosureSEC source: 0001209191-23-038081 · doc4.xml · derivative · entry 1 Imper Vera · CIK 0001902959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,242 Underlying: Common Stock · 30,242 shares Expires 2033-06-14 Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 21:35 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantStock Option (right to buy) · Derivative | 25,789 | $0.00 Strike: $9.67 | $0.00 |
DisclosureSEC source: 0001209191-22-034257 · doc4.xml · derivative · entry 1 Imper Vera · CIK 0001902959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,789 Underlying: Common Stock · 25,789 shares Expires 2032-06-01 Read SEC document |
| December 31, 2021 Filed Jan 6, 2022 23:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantStock Option (Right to Buy) · Derivative | 28,598 | $0.00 Strike: $16.32 | $0.00 |
DisclosureSEC source: 0000899243-22-001259 · doc4.xml · derivative · entry 1 Imper Vera · CIK 0001902959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,598 Underlying: Common Stock · 28,598 shares Expires 2031-12-31 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/36th of the shares subject to the option shall vest monthly over three years from December 31, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.